Neurocognitive Risk With PCSK9 Inhibitors: Need for More Robust Evidence

In a pooled analysis of 14 trials of alirocumab, Robinson et al. (1) reported the safety of alirocumab even with very low levels of low-density lipoprotein cholesterol (LDL). They found that 25% of the patients who received alirocumab had an LDL level

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of the American College of Cardiology 2017-05, Vol.69 (19), p.2468-2469
Hauptverfasser:	Khan, Abdur Rahman, Riaz, Haris, Farid, Talha, Bolli, Roberto
Format:	Artikel
Sprache:	eng
Schlagworte:	Cardiology Cardiovascular diseases Cholesterol Clinical trials Cognition Cognitive ability Health risks Heart Hypercholesterolemia Incidence Inhibitor drugs Kexin Lipids Low density lipoprotein Patients Populations Protease Protease inhibitors Proteinase Proteinase inhibitors Risk Serine Side effects Subtilisin Therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In a pooled analysis of 14 trials of alirocumab, Robinson et al. (1) reported the safety of alirocumab even with very low levels of low-density lipoprotein cholesterol (LDL). They found that 25% of the patients who received alirocumab had an LDL level
ISSN:	0735-1097 1558-3597
DOI:	10.1016/j.jacc.2017.02.063